Document Detail

17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.
MedLine Citation:
PMID:  20646760     Owner:  NLM     Status:  MEDLINE    
The goal of this study was to ascertain the specific effects of 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) treatment in human acute myelogenous leukemia (AML). Four human leukemia cell lines were treated with varying doses of 17-AAG followed by analysis of toxicity, apoptosis, proliferation, and cell cycle. Cell cycle analysis revealed that the cells accumulate in G2/M phase within 96 h of treatment, although the effect was not equivalent among the cell lines. p21, p53 expression and MDR1 activity were among the possible mechanisms uncovered for the differing responses. Exploiting these differences may allow for more effective combinatory treatments in patients with AML.
Jennifer M Napper; Vincent E Sollars
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2010-06-19
Journal Detail:
Title:  Leukemia research     Volume:  34     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-09-27     Completed Date:  2010-11-03     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1493-500     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Department of Biochemistry and Microbiology, Joan C. Edwards School of Medicine, Marshall University, One John Marshall Drive, Huntington, WV 25755, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects
Benzoquinones / pharmacology*,  therapeutic use,  toxicity
Cell Cycle / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Cyclin-Dependent Kinase Inhibitor p21
G2 Phase / drug effects
Lactams, Macrocyclic / pharmacology*,  therapeutic use,  toxicity
Leukemia, Myeloid, Acute / drug therapy*
P-Glycoprotein / analysis
Tumor Suppressor Protein p53 / analysis
Grant Support
1R03 CA129790/CA/NCI NIH HHS; 5P20RR016477/RR/NCRR NIH HHS; 5P20RR020180/RR/NCRR NIH HHS
Reg. No./Substance:
0/ABCB1 protein, human; 0/Benzoquinones; 0/CDKN1A protein, human; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Lactams, Macrocyclic; 0/P-Glycoprotein; 0/Tumor Suppressor Protein p53; 4GY0AVT3L4/tanespimycin
Comment In:
Leuk Res. 2010 Nov;34(11):1422-3   [PMID:  20638126 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activation of store-operated I(CRAC) by hydrogen peroxide.
Next Document:  Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatin...